Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far
Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interac...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-10-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/2946 |
id |
doaj-450440e5ae944c179b55573e971ba7d9 |
---|---|
record_format |
Article |
spelling |
doaj-450440e5ae944c179b55573e971ba7d92020-11-25T01:56:48ZengPAGEPress PublicationsHematology Reports2038-83222038-83302011-10-0132e16e1610.4081/hr.2011.e161695Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so farJosé Antonio Morales-Molina0Juan Enrique Martínez-de la Plata1Olivia Urquízar-Rodríguez2María Angustias Molina-Arrebola3Pharmacy Department, Hospital de Poniente, El Ejido, AlmeríaPharmacy Department, Hospital de Poniente, El Ejido, AlmeríaPharmacy Department, Hospital de Poniente, El Ejido, AlmeríaHaematology Department, Hospital de Poniente, El Ejido, AlmeríaPulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0-3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time.http://www.pagepress.org/journals/index.php/hr/article/view/2946acenocoumarol, bosentan, drug interactions, warfarin, HIV patients |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
José Antonio Morales-Molina Juan Enrique Martínez-de la Plata Olivia Urquízar-Rodríguez María Angustias Molina-Arrebola |
spellingShingle |
José Antonio Morales-Molina Juan Enrique Martínez-de la Plata Olivia Urquízar-Rodríguez María Angustias Molina-Arrebola Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far Hematology Reports acenocoumarol, bosentan, drug interactions, warfarin, HIV patients |
author_facet |
José Antonio Morales-Molina Juan Enrique Martínez-de la Plata Olivia Urquízar-Rodríguez María Angustias Molina-Arrebola |
author_sort |
José Antonio Morales-Molina |
title |
Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_short |
Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_full |
Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_fullStr |
Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_full_unstemmed |
Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far |
title_sort |
bosentan and oral anticoagulants in hiv patients: what we can learn of cases reported so far |
publisher |
PAGEPress Publications |
series |
Hematology Reports |
issn |
2038-8322 2038-8330 |
publishDate |
2011-10-01 |
description |
Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0-3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time. |
topic |
acenocoumarol, bosentan, drug interactions, warfarin, HIV patients |
url |
http://www.pagepress.org/journals/index.php/hr/article/view/2946 |
work_keys_str_mv |
AT joseantoniomoralesmolina bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar AT juanenriquemartinezdelaplata bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar AT oliviaurquizarrodriguez bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar AT mariaangustiasmolinaarrebola bosentanandoralanticoagulantsinhivpatientswhatwecanlearnofcasesreportedsofar |
_version_ |
1724977620613857280 |